Galapagos Finalizes Binding Agreement with Gilead for Ouro Medicines' T-Cell Engager Program, Gains $500M Strategic Flexibility

summarizeSummary

Galapagos NV has entered into a binding agreement with Gilead Sciences to collaborate on Ouro Medicines' clinical-stage T cell engager program, involving a significant co-investment and securing future royalties. The deal also grants Galapagos $500 million in independent cash for strategic transactions, including potential share buybacks.

check_boxKey Events

• Binding Collaboration Agreement Finalized

  Galapagos and Gilead have entered into a binding agreement to advance Ouro Medicines' clinical-stage T cell engager program, gamgertamig, for autoimmune diseases. This formalizes previous 'advanced discussions' announced on March 23rd.

• Significant Co-Investment in Ouro Medicines

  Galapagos will contribute 50% of the upfront acquisition cost ($837.5 million) and 50% of contingent milestone payments (up to $250 million) for Ouro Medicines, acquiring a high-potential clinical asset.

• Future Revenue Streams and Milestones

  Galapagos is eligible for up to $100 million in development milestones and tiered royalties of 20-23% on net sales of gamgertamig, with Gilead responsible for global commercialization outside Keymed's territories.

• Enhanced Strategic and Financial Flexibility

  A key component is an 'OLCA Waiver' that designates $500 million of Galapagos' cash for independent R&D or strategic transactions, including up to $150 million for potential share buybacks or other capital distributions.

auto_awesomeAnalysis

This filing formalizes the previously announced collaboration between Galapagos and Gilead regarding Ouro Medicines' clinical-stage T cell engager program, gamgertamig. Galapagos will co-invest $837.5 million upfront and up to $250 million in contingent milestones, acquiring a high-potential asset with Fast Track and Orphan Drug Designations expected to enter registrational studies in 2027. The agreement provides Galapagos with tiered royalties of 20-23% on net sales and additional development milestones. Crucially, the deal includes an "OLCA Waiver" that frees up $500 million of Galapagos' cash for independent strategic transactions, including up to $150 million for potential share repurchases. This significantly enhances Galapagos' financial flexibility and strategic autonomy, marking a major step in its transformation and capital allocation strategy.